Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Cattori, V; Weibel, B; Lutz, H (2011). Inhibition of feline leukemia virus replication by the integrase inhibitor raltegravir. Veterinary Microbiology, 152(1-2):165-168.

Full text not available from this repository.

Abstract

The oncogenic gammaretrovirus Feline leukemia virus (FeLV) has been the leading cause of death among domestic cats until the introduction of efficient diagnostics and vaccines in the late 1980s. So far, no efficient treatment for viremic animals is available. Hence, use of the FeLV model to evaluate antiretroviral therapies applied to HIV is a timely task. The efficacy of the integrase inhibitor Raltegravir, which is widely used for the treatment of HIV in humans, has been assessed in vitro for the FeLV-A/Glasgow-1 strain. EC(50) values for FeLV-A inhibition in feline cell lines are in the range of that observed for HIV and xenotropic murine leukemia virus-related gammaretrovirus. Therefore, Raltegravir may be a potential therapeutical agent for felids with progressive FeLV infection.

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Veterinary Clinic > Department of Farm Animals > Clinical Laboratory
DDC:570 Life sciences; biology
630 Agriculture
Language:English
Date:2011
Deposited On:25 Aug 2011 08:49
Last Modified:27 Nov 2013 20:05
Publisher:Elsevier
ISSN:0378-1135
Publisher DOI:10.1016/j.vetmic.2011.03.039
PubMed ID:21570781
Citations:Web of Science®. Times Cited: 2
Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page